ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.

Journal

Biochemical Society Transactions

Author(s)

RoulinD., DemartinesN., DormondO.

ISSN

1470-8752 (Electronic)

ISSN-L

0300-5127

Publication state

Published

Issued date

2011

Volume

39

Number

2

Pages

492-494

Language

english

Abstract

Targeting mTOR (mammalian target of rapamycin) is an effective approach in the treatment of advanced RCC (renal cell carcinoma). Rapamycin-like drugs (rapalogues) have shown clinical activities and have been approved for the treatment of RCC. Recently, with the development of ATP-competitive inhibitors of mTOR, therapies targeting mTOR have entered a new era. Here, we discuss the biological relevance of blocking mTOR in RCC and review the mechanisms of action of rapalogues in RCC. We also advance some perspectives on the use of ATP-competitive inhibitors of mTOR in RCC.